Page R C, Hattersley A T, Levy J C, Barrow B, Patel P, Lo D, Wainscoat J S, Permutt M A, Bell G I, Turner R C
Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, UK.
Diabet Med. 1995 Mar;12(3):209-17. doi: 10.1111/j.1464-5491.1995.tb00460.x.
The clinical characteristics of subjects with a missense glucokinase mutation, gly299-->arg, were studied in a large pedigree, BX, initially characterized by some members having Maturity Onset Diabetes of the Young (MODY). Glucose tolerance, beta cell function and insulin sensitivity were measured with Homeostasis Model Assessment (HOMA) and with a 'Continuous Infusion of Glucose with Model Assessment' (CIGMA) test. Diabetic complications were clinically assessed. Subjects with glucokinase gly299-->arg were the same age, height, and obesity as the subjects without the mutation. Diabetes was usually asymptomatic at diagnosis and was treated with diet alone in 15 of the 18 subjects. Five of the 11 adult females had been diagnosed when they developed gestational diabetes. The fasting plasma glucose concentrations at the time of study were 4.3-12.6 mmol l-1, with the higher levels being in the more obese (p < 0.05) and in the older subjects (p < 0.05). In subjects with the mutation, beta cell function was impaired, being geometric mean 63% (normal-100%) compared with 126% in the subjects without the mutation (p < 0.001) measured by HOMA and in a subset assessed by CIGMA 59% and 127% (p < 0.01), respectively. There was no difference in fasting insulin concentrations, insulin sensitivity, lipid concentrations or blood pressure between the groups. The haemoglobin A1c was raised (mean 6.5% compared with 5.5% in the subjects without the mutation), but microvascular and macrovascular complications were uncommon. The subjects with the mutation did not have microalbuminuria but had an impaired vibration perception threshold compared with subjects without the mutation.(ABSTRACT TRUNCATED AT 250 WORDS)
在一个大型家系BX中,对携带错义型葡萄糖激酶突变(gly299→arg)的受试者的临床特征进行了研究。该家系最初的特征是一些成员患有青年发病的成年型糖尿病(MODY)。采用稳态模型评估(HOMA)和“葡萄糖持续输注模型评估”(CIGMA)试验来测量葡萄糖耐量、β细胞功能和胰岛素敏感性。对糖尿病并发症进行了临床评估。携带葡萄糖激酶gly299→arg突变的受试者与未携带该突变的受试者年龄、身高和肥胖程度相同。糖尿病在诊断时通常无症状,18名受试者中有15名仅通过饮食治疗。11名成年女性中有5名在患妊娠期糖尿病时被诊断出患有该病。研究时的空腹血浆葡萄糖浓度为4.3 - 12.6 mmol/L,较高水平出现在肥胖程度更高(p < 0.05)和年龄较大的受试者中(p < 0.05)。在携带突变的受试者中,β细胞功能受损,通过HOMA测量,几何平均值为63%(正常为100%),而未携带突变的受试者为126%(p < 0.001);在通过CIGMA评估的一个亚组中,分别为59%和127%(p < 0.01)。两组之间的空腹胰岛素浓度、胰岛素敏感性、血脂浓度或血压没有差异。糖化血红蛋白升高(平均6.5%,未携带突变的受试者为5.5%),但微血管和大血管并发症并不常见。携带突变的受试者没有微量白蛋白尿,但与未携带突变的受试者相比,振动觉阈值受损。(摘要截断于250字)